Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00

Giancarlo Pruneri; Kathryn P. Gray; Andrea Vingiani; Giuseppe Viale; Giuseppe Curigliano; Carmen Criscitiello; István Láng; Thomas Ruhstaller; Lorenzo Gianni; Aron Goldhirsch; Roswitha Kammler; Karen N. Price; Giuseppe Cancello; Elisabetta Munzone; Richard D. Gelber; Meredith M. Regan; Marco Colleoni

doi:10.1007/s10549-016-3863-3

Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00

Giancarlo Pruneri, Kathryn P. Gray, Andrea Vingiani, Giuseppe Viale, Giuseppe Curigliano, Carmen Criscitiello, István Láng, Thomas Ruhstaller, Lorenzo Gianni, Aron Goldhirsch, Roswitha Kammler, Karen N. Price, Giuseppe Cancello, Elisabetta Munzone, Richard D. Gelber, Meredith M. Regan, Marco Colleoni

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article

Abstract

The purpose of this study was to assess the prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in the triple-negative breast cancer (TNBC) cohort of the phase III IBCSG trial 22-00, comparing low-dose oral ‘metronomic’ cyclophosphamide-methotrexate maintenance chemotherapy (CM-maintenance) to no-CM-maintenance in early breast cancer. TILs were evaluated in full-face hematoxylin-and-eosin-stained sections of tumor samples confirmed centrally as TNBC (

Original language	English
Pages (from-to)	323-331
Number of pages	9
Journal	Breast Cancer Research and Treatment
Volume	158
Issue number	2
DOIs	https://doi.org/10.1007/s10549-016-3863-3
Publication status	Published - Jul 1 2016

Keywords

Breast cancer
Low-dose maintenance chemotherapy
Prognosis
Triple negative
Tumor-infiltrating lymphocytes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1007/s10549-016-3863-3

Fingerprint Dive into the research topics of 'Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00'. Together they form a unique fingerprint.

Cite this

Pruneri, G., Gray, K. P., Vingiani, A., Viale, G., Curigliano, G., Criscitiello, C., Láng, I., Ruhstaller, T., Gianni, L., Goldhirsch, A., Kammler, R., Price, K. N., Cancello, G., Munzone, E., Gelber, R. D., Regan, M. M., & Colleoni, M. (2016). Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. Breast Cancer Research and Treatment, 158(2), 323-331. https://doi.org/10.1007/s10549-016-3863-3

Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. / Pruneri, Giancarlo; Gray, Kathryn P.; Vingiani, Andrea; Viale, Giuseppe ; Curigliano, Giuseppe ; Criscitiello, Carmen; Láng, István; Ruhstaller, Thomas; Gianni, Lorenzo; Goldhirsch, Aron; Kammler, Roswitha; Price, Karen N.; Cancello, Giuseppe ; Munzone, Elisabetta; Gelber, Richard D.; Regan, Meredith M.; Colleoni, Marco.

In: Breast Cancer Research and Treatment, Vol. 158, No. 2, 01.07.2016, p. 323-331.

Research output: Contribution to journal › Article

Pruneri, G, Gray, KP, Vingiani, A, Viale, G , Curigliano, G , Criscitiello, C, Láng, I, Ruhstaller, T, Gianni, L, Goldhirsch, A, Kammler, R, Price, KN, Cancello, G , Munzone, E, Gelber, RD, Regan, MM & Colleoni, M 2016, 'Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00', Breast Cancer Research and Treatment, vol. 158, no. 2, pp. 323-331. https://doi.org/10.1007/s10549-016-3863-3

Pruneri, Giancarlo ; Gray, Kathryn P. ; Vingiani, Andrea ; Viale, Giuseppe ; Curigliano, Giuseppe ; Criscitiello, Carmen ; Láng, István ; Ruhstaller, Thomas ; Gianni, Lorenzo ; Goldhirsch, Aron ; Kammler, Roswitha ; Price, Karen N. ; Cancello, Giuseppe ; Munzone, Elisabetta ; Gelber, Richard D. ; Regan, Meredith M. ; Colleoni, Marco. / Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. In: Breast Cancer Research and Treatment. 2016 ; Vol. 158, No. 2. pp. 323-331.

@article{5627e9be48a344ef8f3d919de454686b,

title = "Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00",

abstract = "The purpose of this study was to assess the prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in the triple-negative breast cancer (TNBC) cohort of the phase III IBCSG trial 22-00, comparing low-dose oral {\textquoteleft}metronomic{\textquoteright} cyclophosphamide-methotrexate maintenance chemotherapy (CM-maintenance) to no-CM-maintenance in early breast cancer. TILs were evaluated in full-face hematoxylin-and-eosin-stained sections of tumor samples confirmed centrally as TNBC (",

keywords = "Breast cancer, Low-dose maintenance chemotherapy, Prognosis, Triple negative, Tumor-infiltrating lymphocytes",

author = "Giancarlo Pruneri and Gray, {Kathryn P.} and Andrea Vingiani and Giuseppe Viale and Giuseppe Curigliano and Carmen Criscitiello and Istv{\'a}n L{\'a}ng and Thomas Ruhstaller and Lorenzo Gianni and Aron Goldhirsch and Roswitha Kammler and Price, {Karen N.} and Giuseppe Cancello and Elisabetta Munzone and Gelber, {Richard D.} and Regan, {Meredith M.} and Marco Colleoni",

year = "2016",

month = jul,

day = "1",

doi = "10.1007/s10549-016-3863-3",

language = "English",

volume = "158",

pages = "323--331",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer New York LLC",

number = "2",

}

TY - JOUR

T1 - Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00

AU - Pruneri, Giancarlo

AU - Gray, Kathryn P.

AU - Vingiani, Andrea

AU - Viale, Giuseppe

AU - Curigliano, Giuseppe

AU - Criscitiello, Carmen

AU - Láng, István

AU - Ruhstaller, Thomas

AU - Gianni, Lorenzo

AU - Goldhirsch, Aron

AU - Kammler, Roswitha

AU - Price, Karen N.

AU - Cancello, Giuseppe

AU - Munzone, Elisabetta

AU - Gelber, Richard D.

AU - Regan, Meredith M.

AU - Colleoni, Marco

PY - 2016/7/1

Y1 - 2016/7/1

N2 - The purpose of this study was to assess the prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in the triple-negative breast cancer (TNBC) cohort of the phase III IBCSG trial 22-00, comparing low-dose oral ‘metronomic’ cyclophosphamide-methotrexate maintenance chemotherapy (CM-maintenance) to no-CM-maintenance in early breast cancer. TILs were evaluated in full-face hematoxylin-and-eosin-stained sections of tumor samples confirmed centrally as TNBC (

AB - The purpose of this study was to assess the prognostic and predictive value of tumor-infiltrating lymphocytes (TILs) in the triple-negative breast cancer (TNBC) cohort of the phase III IBCSG trial 22-00, comparing low-dose oral ‘metronomic’ cyclophosphamide-methotrexate maintenance chemotherapy (CM-maintenance) to no-CM-maintenance in early breast cancer. TILs were evaluated in full-face hematoxylin-and-eosin-stained sections of tumor samples confirmed centrally as TNBC (

KW - Breast cancer

KW - Low-dose maintenance chemotherapy

KW - Prognosis

KW - Triple negative

KW - Tumor-infiltrating lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=84976515042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976515042&partnerID=8YFLogxK

U2 - 10.1007/s10549-016-3863-3

DO - 10.1007/s10549-016-3863-3

M3 - Article

AN - SCOPUS:84976515042

VL - 158

SP - 323

EP - 331

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -